3 Reasons to Buy Pfizer Stock for Retirement
Blue-chip dividend-paying stocks should be part of any retirement portfolio, and one of the best of the bunch these days is drugmaker Pfizer (symbol PFE).


Blue-chip dividend-paying stocks should be part of any retirement portfolio, and one of the best of the bunch these days is drugmaker Pfizer (symbol PFE). Here are three reasons we like the stock for retirees.
Figures are as of Dec. 29 unless otherwise indicated.

A Big, Steady Business
With sales estimated at more than $51 billion in 2016, Pfizer ranks as one of the world’s largest pharmaceutical companies. The firm muddled through a few slow years after its patent for the cholesterol drug Lipitor expired in 2011, but it’s past that now. Investments in research and development, along with acquisitions, have resulted in several hit drugs on the market, including Ibrance, to treat breast cancer, blood thinner Eliquis and Xeljanz, a treatment for rheumatoid arthritis. Pfizer is now working on 94 drugs, including 41 in late-stage development to treat various cancers, diabetes and other ailments.
Pfizer is also expanding into the fast-growing market for generic versions of biotech drugs. The firm recently launched a “biosimilar” knockoff of Remicade, Johnson & Johnson’s (symbol JNJ) best-selling arthritis treatment with more than $5 billion in annual sales. Pfizer aims to sell its biosimilar version at a 15% discount -- savings that may be passed on to patients, making the deal hard to pass up.
Finally, Pfizer is using its massive financial muscle to make deals that are fueling growth. Its 2015 merger with Hospira, the company behind the Remicade biosimilar, has added more than $1 billion in quarterly sales to Pfizer’s revenues. The company also recently completed a $14 billion deal to buy prostate-cancer drugmaker Medivation.

Attractively Priced “Defensive” Stock
Whether the economy is expanding or contracting, demand for medications remains steady. That makes Pfizer one of the stronger defensive stocks you can buy. The shares fell by 16% in 2008, a year in which Standard & Poor’s 500-stock index declined by 37% (including dividends). Pfizer has trailed the S&P 500 over the past five years. But the stock has produced annualized returns of 11.6% (including dividends) in that stretch--a respectable showing for such a large company.
The shares look relatively inexpensive, too. Trading at about 14 times estimated earnings for 2017, the stock looks much cheaper than the S&P 500, which has a price-earning ratio of 17. Pfizer does trade at a higher trailing P/E ratio than its average over the past five years, according to Morningstar. But the past five years were a transition period between slowing sales of off-patent drugs and the emergence of new hits. Pfizer’s prospects look brighter today, with a stronger roster of drugs in development and several acquisitions that should help produce solid earnings for years.

Dependable Dividends
Many retirees need a reliable income stream, and Pfizer stacks up well in that department. The stock currently yields 3.6%—more than you can earn from a 10-year Treasury bond (2.5%) or the S&P 500 (2.1%).
Investors can also take comfort in the fact that Pfizer has paid uninterrupted dividends every year since 1980. The company has raised its payout every year since 2010. And Pfizer should have no trouble making regular payments. Analysts estimate that the company will distribute more than $7 billion in dividends in 2017, easily covered by net income of $15.9 billion.
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

Dan Burrows is Kiplinger's senior investing writer, having joined the publication full time in 2016.
A long-time financial journalist, Dan is a veteran of MarketWatch, CBS MoneyWatch, SmartMoney, InvestorPlace, DailyFinance and other tier 1 national publications. He has written for The Wall Street Journal, Bloomberg and Consumer Reports and his stories have appeared in the New York Daily News, the San Jose Mercury News and Investor's Business Daily, among many other outlets. As a senior writer at AOL's DailyFinance, Dan reported market news from the floor of the New York Stock Exchange.
Once upon a time – before his days as a financial reporter and assistant financial editor at legendary fashion trade paper Women's Wear Daily – Dan worked for Spy magazine, scribbled away at Time Inc. and contributed to Maxim magazine back when lad mags were a thing. He's also written for Esquire magazine's Dubious Achievements Awards.
In his current role at Kiplinger, Dan writes about markets and macroeconomics.
Dan holds a bachelor's degree from Oberlin College and a master's degree from Columbia University.
Disclosure: Dan does not trade individual stocks or securities. He is eternally long the U.S equity market, primarily through tax-advantaged accounts.
-
Rally Fades on Mixed AI Revolution News: Stock Market Today
All three main U.S. equity indexes opened higher but closed lower as a seven-session winning streak for the S&P 500 came to an end.
-
Stretch Your Holiday Shopping Budget Further with These Under-$50 Gifts That Don't Feel Cheap
Amazon October Prime Day is the perfect chance to nab some under-$50 gifts that feel more expensive than they are (because normally they would be).
-
Rally Fades on Mixed AI Revolution News: Stock Market Today
All three main U.S. equity indexes opened higher but closed lower as a seven-session winning streak for the S&P 500 came to an end.
-
S&P, Nasdaq Hit New Highs: Stock Market Today
A late-day rally wasn't enough to lift the Dow into the green as its six-session winning streak came to an end.
-
Dow Adds 238 Points as UNH, CAT Pop: Stock Market Today
The lack of a September jobs report didn't seem to worry market participants, with the data delayed due to the ongoing government shutdown.
-
Stocks at New Highs as Shutdown Drags On: Stock Market Today
The Nasdaq Composite, S&P 500 and Dow Jones Industrial Average all notched new record closes Thursday as tech stocks gained.
-
S&P 500 Sees New Highs on Shutdown Day: Stock Market Today
Most of its components were in the red, but the S&P 500 Index still managed to hit a new intraday all-time high.
-
Stocks Close September on a High Note: Stock Market Today
A little bit of late risk-on behavior was enough to lift stocks into the green on the last day of September.
-
Investors Take Stock of Shutdown Talk: Stock Market Today
Whether we'll have a Jobs Friday this week depends on if we have a government shutdown in Washington.
-
Dow Adds 300 Points, Ends Losing Streak: Stock Market Today
The Dow, the S&P 500 and the Nasdaq head into the weekend on high notes after posting gains for the first time since Monday.